Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) shares hit a new 52-week high on Wednesday . The stock traded as high as $40.17 and last traded at $38.86, with a volume of 194791 shares. The stock had previously closed at $38.25.
Wall Street Analyst Weigh In
AVLN has been the subject of a number of research analyst reports. Guggenheim assumed coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $80.00 target price for the company. Jefferies Financial Group began coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $52.00 price target on the stock. Zacks Research raised Avalyn Pharma to a "hold" rating in a research note on Wednesday, May 27th. Wall Street Zen cut Avalyn Pharma from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Evercore initiated coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They set an "outperform" rating and a $51.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $60.00.
View Our Latest Analysis on Avalyn Pharma
Avalyn Pharma Stock Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The stock's fifty day simple moving average is $30.55. The company has a market cap of $1.72 billion and a PE ratio of -1.78.
Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.03) by $0.05. On average, equities research analysts anticipate that Avalyn Pharma Inc. will post -3.81 EPS for the current fiscal year.
Hedge Funds Weigh In On Avalyn Pharma
A hedge fund recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp bought a new position in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned 0.09% of Avalyn Pharma as of its most recent filing with the Securities and Exchange Commission.
Avalyn Pharma Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Avalyn Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.
While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
